CD40LG and infection: Of the 26 patients with intermittent infection and of the 10 uninfected, 17 (47.2%) patients experienced a new or recent infection with P. aeruginosa (within 6 months of obtaining the baseline sample) and received eradication treatment; a second blood sample was obtained in 13 patients to evaluate the performance of sCD40L at the end of eradication treatment.